Xiying Shao1, Xian Wang2, Xiaohong Xu3, Jianguo Feng3, Mark Han4, Han Zhang4, Zhan-Hong Chen1, Sheng Wang3, Yi-Min Zang3, Ping Huang1, Hongchuan Jin2, Xiaojia Wang5. 1. Department of Medical Oncology, Zhejiang Cancer Hospital Hangzhou, China. 2. Department of Medical Oncology, Sir Runrun Shaw Hospital, School of Medicine, Zhejiang University Hangzhou, China. 3. Zhejiang Cancer Institute, Zhejiang Province Key Laboratory of Diagnosis and Treatment Technology on Thoracic Oncology Hangzhou, China. 4. Hangzhou Polar Gene Co., LTD Hangzhou, China. 5. Department of Medical Oncology, Zhejiang Cancer Hospital Hangzhou, China ; Department of Medical Oncology, Sir Runrun Shaw Hospital, School of Medicine, Zhejiang University Hangzhou, China.
Abstract
BACKGROUND: HER-2 overexpression is an independent predictor for poor prognosis of breast cancer patients. Recently, extracellular domain of HER-2 (ECD) was found detectable in the serum of breast cancer patients. In this prospective study, we wonder whether ECD levels predict the clinical outcome of metastatic breast cancer patients. METHODS: ECD were measured in 190 women with metastatic breast cancer. Chi-square test was performed to determine the relationship between ECD status and clinical outcomes. Kaplan-Meier curves were applied for survival analysis. RESULTS: Elevated ECD levels were significantly associated with short-term response to Herceptin treatment. The median PFS was significantly longer in ECD-Low patients. The patients who remained low ECD levels or achieved low ECD levels after treatments have significantly longer PFS than those whose levels remained high or converted from low to high. CONCLUSIONS: Overall, our results support the clinical utility of measuring serum HER2 ECD levels in patients with advanced breast cancer. Baseline and serial measurements of serum ECD levels are reliably predictive of clinical outcome of breast cancer patients.
BACKGROUND:HER-2 overexpression is an independent predictor for poor prognosis of breast cancerpatients. Recently, extracellular domain of HER-2 (ECD) was found detectable in the serum of breast cancerpatients. In this prospective study, we wonder whether ECD levels predict the clinical outcome of metastatic breast cancerpatients. METHODS: ECD were measured in 190 women with metastatic breast cancer. Chi-square test was performed to determine the relationship between ECD status and clinical outcomes. Kaplan-Meier curves were applied for survival analysis. RESULTS: Elevated ECD levels were significantly associated with short-term response to Herceptin treatment. The median PFS was significantly longer in ECD-Lowpatients. The patients who remained low ECD levels or achieved low ECD levels after treatments have significantly longer PFS than those whose levels remained high or converted from low to high. CONCLUSIONS: Overall, our results support the clinical utility of measuring serum HER2 ECD levels in patients with advanced breast cancer. Baseline and serial measurements of serum ECD levels are reliably predictive of clinical outcome of breast cancerpatients.
Entities:
Keywords:
Epidermal growth factor receptor-2 (EGFR-2); extracellular domain; metastatic breast cancer
Authors: Wolfgang J Köstler; Barbara Schwab; Christian F Singer; Rainer Neumann; Ernst Rücklinger; Thomas Brodowicz; Sandra Tomek; Monika Niedermayr; Michael Hejna; Günther G Steger; Michael Krainer; Christoph Wiltschke; Christoph C Zielinski Journal: Clin Cancer Res Date: 2004-03-01 Impact factor: 12.531
Authors: Francisco J Esteva; Vicente Valero; Daniel Booser; Laura T Guerra; James L Murray; Lajos Pusztai; Massimo Cristofanilli; Banu Arun; Bita Esmaeli; Herbert A Fritsche; Nour Sneige; Terry L Smith; Gabriel N Hortobagyi Journal: J Clin Oncol Date: 2002-04-01 Impact factor: 44.544
Authors: D J Slamon; W Godolphin; L A Jones; J A Holt; S G Wong; D E Keith; W J Levin; S G Stuart; J Udove; A Ullrich Journal: Science Date: 1989-05-12 Impact factor: 47.728
Authors: G B Cook; I E Neaman; J L Goldblatt; D R Cambetas; M Hussain; D Lüftner; K K Yeung; D W Chan; M K Schwartz; W J Allard Journal: Anticancer Res Date: 2001 Mar-Apr Impact factor: 2.480
Authors: Alvaro Moreno-Aspitia; David W Hillman; Stephen H Dyar; Kathleen S Tenner; Julie Gralow; Peter A Kaufman; Nancy E Davidson; Jacqueline M Lafky; Monica M Reinholz; Wilma L Lingle; Leila A Kutteh; Walter P Carney; Amylou C Dueck; Edith A Perez Journal: Cancer Date: 2013-06-06 Impact factor: 6.860
Authors: Walter P Carney; Rainer Neumann; Allan Lipton; Kim Leitzel; Suhail Ali; Christopher P Price Journal: Clin Chem Date: 2003-10 Impact factor: 8.327